Journal
ONCOTARGETS AND THERAPY
Volume 11, Issue -, Pages 4829-4835Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S164574
Keywords
adenosquamous carcinoma of the lung; clinicopathological characteristics; histogenesis; prognosis; chemotherapy; targeted therapy; immunotherapy
Categories
Funding
- Public Welfare Technology Application Studies Program of Zhejiang Province [2016C33118]
- 1022 Talent Training Program of Zhejiang Cancer Hospital
Ask authors/readers for more resources
Adenosquamous carcinoma of the lung (ASC), a relatively rare subtype of non-small-cell lung cancer, is defined as a malignancy containing components of lung adenocarcinoma (ADC) and lung squamous cell carcinoma (SCC). Although ASC has biological characteristics of ADC and SCC, it is not by any means a simple hybrid of two components above. It is extremely difficult to diagnose preoperatively; pathology of surgically resected gross specimen is the most effective means for adequate diagnosis of ASC. Platinum-based postoperative adjuvant chemotherapy for at least four cycles can significantly improve the survival in stage III patients with ASC. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib and gefitinib can be the effective therapeutic strategies for advanced EGFRmutant ASC. The studies of crizotinib in the treatment of patients with ASC are very limited. Immune checkpoint blockade therapy may be a potential treatment choice for ASC patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available